Considerable evidence indicates that the glycoprotein (GP) lIb/Illa complex on human platelets functions as a receptor for fibrinogen, but little is known about the mechanism of receptor "exposure." To investigate this mechanism, our previously described murine monoclonal antibody (10E5) and a new monoclonal antibody (7E3), both of which block the binding of fibrinogen to platelets and bind to GPIIb and/or GPIIIa, were radiolabeled and their rates of binding to native and ADP-activated platelets were studied. At low concentrations, 1251-10E5 bound nearly equally rapidly to both native and activated platelets, whereas`2I-7E3 bound slowly to native platelets and much more rapidly to activated platelets. This increased rate of 7E3 binding is unlikely to be due to an increase in the number of GPIIb/IIla sites on the surface of activated platelets because: (a) the rate of 10E5 binding was unchanged; (b) the total number of surface GPIIb/IIIa sites increased by only 2-10% with activation as judged by equilibrium binding of near-saturating concentrations of 10E5 and 7E3, and (c) there was <1% release of platelet factor 4 with activation, indicating minimal fusion of a-granule membranes (a potential source of GPIIb/IIIa) with the plasma membrane. Other activators (epinephrine, thrombin, and ionophore A 23187) also increased the rate of 7E3 binding, as did digestion of platelets with chymotrypsin. Aspirin did not affect the rate of binding of 7E3, whereas apyrase, prostaglandin El, and dibucaine all inhibited the enhancement of the 7E3-binding rate produced by ADP. These data provide evidence for an activation-dependent change in the conformation and/or microenvironment of the GPIIb/IIIa complex, and offer a method of studying the receptor exposure mechanism that does not rely on the binding of fibrinogen itself.
Introduction
The binding of macromolecular ligands, most notably fibrinogen, to the glycoprotein lIb/Illa (GPIIb/IIIa)' complex on the platelet surface after appropriate stimulation must be This work was presented in part as an abstract to the meeting of the American Society of Hematology, December 1984. Received for publication 7 September 1984 and in revised form 26 February 1985.
1. Abbreviations used in this paper: ACD, acid-citrate dextrose; GFP, gel-filtered platelets; GP, glycoprotein; HBMT, Hepes-buffered, modified Tyrode's solution; PF-4, platelet factor 4; PGE1, prostaglandin El; PRP, platelet-rich plasma.
crucial for normal platelet function since patients with Glanzmann's thrombasthenia, whose platelet GPI1b/Illa complex is either deficient or abnormal, have a severe bleeding disorder (1) (2) (3) (4) (5) (6) (7) . Still unresolved, however, is the molecular mechanism by which agonist activation results in the ability of this complex to bind these ligands, the process commonly termed receptor "exposure." One leading hypothesis is that agonist activation induces a change in either the conformation and/or microenvironment of GPIIb/IIIa such that the ligands can interact with a portion of the complex possessing a high binding affinity, but until now the only way to assess such a change was by inference from the binding of fibrinogen and the other ligands themselves. The present study, employing two different murine monoclonal antibodies, each directed at a site on the GPIIb/IIIa complex, provides independent evidence to support this hypothesis.
Methods
Monoclonal antibodies. The production, screening, purification, characterization, and iodination of antibody 10E5 have been reported in detail previously (8) . The hybridoma cell line producing antibody 7E3 was derived from the same fusion as lOES. 7E3 culture supernatants were positive in the fibrinogen-coated bead screening assay (8) , suggesting the presence of an antibody that blocks the interaction of platelets with fibrinogen. The 7E3 cells were frozen in 10% dimethylsulfoxide-90% fetal calf serum soon after the fusion (7/10/81) and thawed 15 mo later. The cells were subcloned by both the limiting dilution technique (9) and growth in soft agar to insure monoclonality. Antibody was then produced in ascites tumors, and further purified, characterized, and iodinated as reported for lOE5 (8) .
Platelet preparation. Platelet-rich plasma (PRP) was prepared by differential centrifugation of blood anticoagulated with 0.01 vol of 40% trisodium citrate, 0.1 vol of 3.2% trisodium citrate, or 0.14 vol of acidcitrate dextrose solution (ACD-A). Gel-filtered platelets (GFP) were prepared from PRP by chromatography on a 8 X 2.5-cm Sepharose 2B (Pharmacia Fine Chemicals, Piscataway, NJ) column, using a modified Tyrode's buffer (HBMT) containing N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (Hepes) and albumin for elution (0.138 M NaCl, 2.7 mM KCI, 0.4 mM NaH2PO4, 12 mM NaHCO3, 2 mM MgCl2, 0.01 M Hepes, 0.1% glucose, 0.2% bovine serum albumin, pH 7.45) (10). Platelets were counted in an electronic particle counter (Particle Data, Inc., Elmhurst, IL) and aggregation of GFP was performed as previously described (11) , with fibrinogen (2.0 mg/ml; A. B. Kabi, Stockholm, Sweden) being added just before the ADP (Sigma Chemical Co., St. Louis, MO). Platelets from a normal donor and a patient with Glanzmann's thrombasthenia from the Iraqi-Jewish population (12) were washed and solubilized in Triton X-100 for use in radioimmunoelectrophoresis as previously described (13) . To assess the EDTA sensitivity of the epitopes recognized by lOE5 and 7E3, the solubilized normal platelets were incubated with 10 mM EDTA for 30 min at 370C.
Radioimmunoelectrophoresis of solubilized normal, thrombasthenic, or EDTA-treated platelets was performed on premade 1.5% agarose gels in 35 mM barbital buffer, pH 8.6 (Immunoelectrofilm, Kallestad Laboratories, Inc., Austin, TX) as previously described (13 Tris, 20 mM benzamidine, 20 mM N-ethylmaleimide, 100 U/ml trasylol, 50 Mg/ml leupeptin, 10M M D-Phe-Pro-Arg-chloromethyl ketone, 1% Triton X-100, 0.05% sodium azide, pH 7.4, centrifuged to remove platelet debris, and passed over the column. After removal of unbound proteins with 0.15 M NaCl, 0.01 M Tris, 20 mM benzamidine, 20 mM N-ethylmaleimide, 1% Triton X-100, 0.05% sodium azide, pH 7.4, and 1.5 M NaCI, 0.01 M Tris, 5 mM N-ethylmaleimide, 0.05% Triton X-100, pH 7.4, the bound proteins were eluted with 0.05 M diethylamine, 10 mM EDTA, 0.05% Triton X-100, 5 mM N-ethylmaleimide, 0.05% sodium azide, pH 11.5, and characterized by polyacrylamide gel electrophoresis as previously described (8) .
Results

Characterization of antibody 7E3
Antibody 7E3 belongs to the IgG, subclass. At 10 ,g/ml it completely blocks platelet aggregation induced by 5 Table I . lOES binding was rapid and unaffected by prior stimulation with 10 uM ADP, whereas the rate of 7E3 binding to unstimulated platelets was much slower and increased significantly after ADP stimulation. After 1 h, however, the extent of 7E3 binding to unstimulated platelets equaled that for stimulated platelets. When four samples of GFP from the same donor were assayed on different days for the percentage of added 7E3 bound to platelets in 2 min, a consistent difference between buffer-and ADP-treated platelets was observed (buffer = 9.9±0.7% [mean±SEM], ADP = 34.4±2.0%; P < 0.001). A significant difference between the amount of antibody bound to buffer-and ADP-treated platelets within the first several minutes was apparent over a wide range of 7E3 concentrations, whether expressed as the number of molecules bound per platelet or as the percentage of added antibody contained in the platelet pellet (Table II) proteins with a combination of a heterologous antiplatelet antibody and radiolabeled lOE5 or 7E3 antibody. Platelets were solubilized in 1% Triton X-100 and 3-Ml samples were electrophoresed in 1.5% agarose gels as described in the text. Well 3 contained normal platelets, well 4 platelets from 'a patient with Glanzmann thrombasthenia, and well S normal solubilized platelets treated with 10 mM EDTA so as to split the GPIIb/IIla complex. Well 6 lontained normal serum. Arcs were developed by overnight incubation with a combination of activated platelets were studied in more detail. Equilibrium determinations were deemed unsuitable because the effect of ADP reverses before equilibrium is established (see below), and so it was decided to measure the initial off-and on-rates. value for GPIIb/IIIa sites on ADP-treated platelets exceeded the mean value for buffer-treated platelets by <2%, a statistically insignificant variation. When a near-saturating dose of 7E3 antibody was allowed to reach equilibrium, the ADP-treated GFP had a value that was also <2% greater than that for the buffer-treated GFP. To further assess whether release of a-granule contents occurred during the experiments, the supernatants remaining after sedimenting the platelets was assayed for the a-granule protein, PF-4. The supernatant from buffertreated platelets contained 2.4% of the PF-4 releasable by thrombin, and the supernatant from ADP-stimulated platelets contained 3.1%, indicating that ADP induced release of less than 1% of the a-granule contents.
Platelet-rich plasma. ADP also accelerated the rate at which 7E3 bound to platelets in PRP. When 13 samples from seven normal donors were tested for 7E3 binding after a 2-min incubation, buffer-treated platelets bound 18.7±0.7%
(mean±SEM) whereas ADP-treated platelets bound 38.7±1.3% (P < 0.001). The total number of GPIIb/IIIa sites were found to increase 4.4% (n = 3) upon ADP stimulation when judged by the equilibrium binding of a near-saturating concentration of 7E3 antibody and 10.2% (n = 8) upon using a nearsaturating concentration of 10E5, values that failed to achieve statistical significance (P > 0. 15 (Table III) .
Effects of other agonists
Epinephrine increased the rate of '251-7E3 antibody binding to platelets in PRP in a dose-dependent fashion, but not to the same extent as ADP (Table IV) . Epinephrine also produced a slight decrease in the rate of lOES binding to platelets, but again epinephrine was less potent than ADP. Both of these data are consistent with previous studies showing epinephrine to be a less potent inducer of fibrinogen binding to platelets than ADP (18, 19) . As with ADP, epinephrine did not increase the total number of lOE5 binding sites as measured by a nearsaturating concentration of lOES.
Thrombin (0.5 U/ml) and ionophore A 23187 (5 AM) both caused a greater increase in the 2-min binding of 7E3 to GFP than did ADP (Table IV) . The interpretation of these data is complicated, however, in that both agents also significantly increased the total number of lOES and 7E3 molecules that could bind to platelets (Table IV) . The additional binding sites may be derived from a-granule GPIIb/IIIa that becomes associated with the plasma membrane as a result of the induction ofthe release reaction by these agents (see Discussion).
Effects of inhibitors ofplatelet function
Preincubation of PRP with 1 mM acetylsalicyclic acid for 15-20 min at 37°C did not alter the 2-min binding of low doses of 7E3, nor did it inhibit the increase in 2-min 7E3 binding produced by ADP (e.g., in one of three similar experiments, the values for native PRP were 2,140±90 molecules/platelet
[mean±SD] unstimulated and 5,480±150 molecules/platelet after ADP stimulation; the comparable values for acetylsalicylic acid-treated platelets were 2,020±60 molecules/platelet and 5,330±180 molecules/platelet). Apyrase (2 mg/ml; Sigma Chemical Co.) and PGEI (0.1-1.0 MM), agents known to inhibit ADP-induced platelet aggregation, both inhibited the ADP-induced increase in the 2-min binding of 1251-7E3 (Table  V) . They also tended to have a slight effect on the binding of 7E3 to unstimulated platelets, reducing the binding by -10-20%. Dibucaine (1 mM), a local anesthetic that not only inhibits platelet aggregation and release, but also induces morphologic and functional changes in the platelet membrane (20) , not only inhibited the ADP-induced increase in the rate of 7E3 binding, but also decreased the rate of 7E3 binding to untreated platelets by >50% (Table V) .
Effects ofchymotrypsin treatment ofplatelets Under the appropriate circumstances, platelets treated with a-chymotrypsin can bind fibrinogen and aggregate, even in (31) . The present study thus provides the first direct evidence that platelet activation results in a change in the GPIIb/IIIa complex. The 7E3 binding assay also permits analysis of the "exposure" of the GPIIb/IIIa fibrinogen receptor independent of measuring fibrinogen binding itself; thus, factors that may alter fibrinogen rather than the receptor are less likely to confound data interpretation. In addition, as shown with dibucaine, it may help to differentiate inhibitory agents that act directly on the receptor from those that act via inhibition of signal transduction.
The molecular basis for the alteration in GPIIb/IIIa that permits ligand binding is still poorly understood. One attractive hypothesis was that GPIIb and GPIIIa are not complexed in unactivated platelets and that platelet activation results in the formation of GPIIb/IIIa heteroduplexes via calcium release. The weight of evidence currently available from studies using monoclonal antibodies that appear to be specific for the GPIIb/ IlIa complex, however, indicates that GPIIb and GPIIIa probably exist as a complex even on unactivated platelets (15, (32) (33) (34) . Other possibilities include a change in the conformation of the GPIIb/IIIa complex itself or a change in the microenvironment surrounding the GPIIb/IIIa complex. The data from the present study suggest that 10E5 binds to a site on the GPIIb/IIIa complex that is unaffected by the activation process whereas 7E3 binds either preferentially or exclusively with the activated state. This could be due to it exclusively or preferentially recognizing the new conformation of the complex or because the change in the microenvironment permits it to gain access to a GPIIb/IIIa complex that is always in the proper conformation. In that 7E3 does bind, albeit slowly, to unstimulated platelets, there may well be a dynamic equilibrium between the different conformations of the GPIIb/IIIa complex or between the microenvironmental conditions that determine access to the GPIIb/IIIa complex. There are, of course, alternative models, and additional studies will be required to differentiate between the many possibilities.
